Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries
Subjects in Bunionectomy Study Dosed Data Presented at American Society for Pharmacology and Experimental Therapeutics Shows Similar Ropivacaine Pharmacokinetic Curves From CPL-01 Across Multiple Surgeries; Minimal Variability as Compared to Liposomal Bupivacaine SAN DIEGO, June 5, 2023 /PRNewswire/ — Cali Biosciences Co., Ltd. (hereinafter referred to as “Cali” or “Cali Biosciences”), a biopharmaceutical company focused … Read more